Deborah H. Charych - 14 Feb 2023 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
14 Feb 2023
Transactions value $
$0
Form type
4
Date filed
16 Feb 2023, 16:30
Next filing
03 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +250K $0.00 250K 14 Feb 2023 Common Stock 250K $0.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1. The option grant shall be exercisable for a price of $0.039 per option share for ten years from February 14, 2023 and the options will vest in equal monthly installments over the one year period beginning February 15, 2023.